Oramed Pharmaceuticals (ORMP) Projected to Post Quarterly Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) is expected to announce its results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, analysts expect Oramed Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oramed Pharmaceuticals Trading Down 1.3%

ORMP stock opened at $2.36 on Tuesday. The stock has a 50-day moving average price of $2.36 and a two-hundred day moving average price of $2.24. Oramed Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $3.09. The company has a market cap of $96.77 million, a PE ratio of -6.74 and a beta of 1.62.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ORMP shares. Wall Street Zen upgraded Oramed Pharmaceuticals to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Oramed Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. Jane Street Group LLC boosted its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 35.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,173 shares of the biotechnology company’s stock after buying an additional 17,510 shares during the quarter. Jane Street Group LLC owned 0.16% of Oramed Pharmaceuticals worth $144,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.